Harrow Health, Inc. (HROW)

Market Cap	637.71M
Revenue (ttm)	88.60M
Net Income (ttm)	-14.09M
Shares Out	29.97M
EPS (ttm)	-0.51
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	79,016
Open	21.00
Previous Close	20.80
Day's Range	20.95 - 21.67
52-Week Range	5.40 - 22.35
Beta	0.16
Analysts	Buy
Price Target	23.26 (+9.1%)
Earnings Date	May 4, 2023

About HROW

Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commerc...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1998
• Employees: 182
• Stock Exchange: NASDAQ
• Ticker Symbol: HROW

Financial Performance

In 2022, Harrow Health's revenue was $88.60 million, an increase of 22.24% compared to the previous year's $72.48 million. Losses were -$14.09 million, -23.77% less than in 2021.

Analyst Forecast

According to 10 analysts, the average rating for HROW stock is "Buy." The 12-month stock price forecast is $23.26, which is an increase of 9.10% from the latest price.

Price Target

$23.26

(9.10% upside)

Analyst Consensus: Buy